What is NRX-100 Expanded Access?
The newly approved NRX-100 expanded access program allows doctors to request this preservative-free intravenous ketamine for patients in suicidal crisis who have not responded to other treatments. Unlike typical ketamine formulations, NRX-100 does not contain benzethonium chloride, a preservative that has not been well studied for long-term safety.
This step marks an important shift in how suicidal ideation in depression, including bipolar depression, can be addressed. Patients who qualify for expanded access typically face life-threatening conditions where standard therapies no longer work.
Why is NRX-100 Significant?
The U.S. Food and Drug Administration (FDA) granted NRX-100 Fast Track designation because of its ability to fill an urgent clinical gap. Clinical trials have shown intravenous ketamine to rapidly reduce suicidal thoughts. For example, one Columbia University study reported that 55% of patients receiving IV ketamine experienced at least a 50% reduction in suicidality compared to 30% with an active comparator.
These results stand out because intranasal forms of ketamine have not consistently produced the same benefits. For patients in immediate danger of self-harm, the speed and reliability of IV ketamine treatment could be life-saving.
How NRX-100 Works
NRX-100 acts on N-methyl-D-aspartate (NMDA) receptors, a pathway tied to rapid antidepressant effects. By targeting these receptors, the drug can quickly reduce suicidal ideation. However, because the effects of ketamine are often short-lived, it is especially useful in managing acute crises until longer-term treatment strategies are in place.
With FDA recognition, NRX-100 is now considered a standalone option, broadening access beyond its earlier approval only in combination with other medications.
Who Can Access NRX-100?
To qualify for the NRX-100 expanded access program, patients must:
- Have a life-threatening condition, such as suicidal depression.
- Have not responded to other available treatments.
- Undergo a physician’s benefit-risk evaluation based on medical history and current condition.
Physicians can submit requests directly through NRx Pharmaceuticals, and additional guidance for patients and clinicians is available via the FDA’s Expanded Access framework.
Looking Ahead
NRX-100 represents both medical progress and a compassionate response to the urgent needs of patients with suicidal depression. By combining scientific innovation with an expanded access pathway, this treatment has the potential to save lives while shaping the future of ketamine therapy in psychiatry.
References
- NRx Pharmaceuticals. NRx Pharmaceuticals, Inc. announces expanded access policy for NRX-100 (preservative-free ketamine). August 27, 2025. https://www.globenewswire.com/news-release/2025/08/27/3139980/0/en/NRx-Pharmaceuticals-Inc-NASDAQ-NRXP-Announces-Expanded-Access-Policy-for-NRX-100-preservative-free-ketamine.html?utm_source=chatgpt.com
- Kuntz L. FDA grants Fast Track designation for NRX-100 for suicidal ideation in patients with depression, including bipolar depression. Psychiatric Times. August 11, 2025. https://www.psychiatrictimes.com/view/fda-fast-track-designation-for-nrx-100-for-suicidal-ideation-in-patients-with-depression-including-bipolar-depression?utm_source=chatgpt.com